These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30321802)

  • 1. Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives.
    Zhang S; Qi F; Fang X; Yang D; Hu H; Huang Q; Kuang C; Yang Q
    Eur J Med Chem; 2018 Dec; 160():133-145. PubMed ID: 30321802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
    Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives.
    Pantouris G; Loudon-Griffiths J; Mowat CG
    J Enzyme Inhib Med Chem; 2016; 31(sup1):70-78. PubMed ID: 27096472
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
    Cui G; Lai F; Wang X; Chen X; Xu B
    Eur J Med Chem; 2020 Feb; 188():111985. PubMed ID: 31881488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors.
    Li J; Li Y; Yang D; Hu N; Guo Z; Kuang C; Yang Q
    Eur J Med Chem; 2016 Nov; 123():171-179. PubMed ID: 27475108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening.
    Wu JS; Lin SY; Liao FY; Hsiao WC; Lee LC; Peng YH; Hsieh CL; Wu MH; Song JS; Yueh A; Chen CH; Yeh SH; Liu CY; Lin SY; Yeh TK; Hsu JT; Shih C; Ueng SH; Hung MS; Wu SY
    J Med Chem; 2015 Oct; 58(19):7807-19. PubMed ID: 26348881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
    Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
    Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
    Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
    Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
    Yang S; Li X; Hu F; Li Y; Yang Y; Yan J; Kuang C; Yang Q
    J Med Chem; 2013 Nov; 56(21):8321-31. PubMed ID: 24099220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
    Badawy AA
    Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDO1 and TDO inhibitory evaluation of analogues of the marine pyrroloiminoquinone alkaloids: Wakayin and Tsitsikammamines.
    Levy T; Marchand L; Stroobant V; Pilotte L; Van den Eynde B; Rodriguez F; Delfourne E
    Bioorg Med Chem Lett; 2021 May; 40():127910. PubMed ID: 33711443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking studies of antidepressants against single crystal structure of tryptophan 2, 3-dioxygenase using Molegro Virtual Docker software.
    Dawood S; Zarina S; Bano S
    Pak J Pharm Sci; 2014 Sep; 27(5 Spec no):1529-39. PubMed ID: 25176248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase.
    Hua S; Chen F; Xu G; Gou S
    Eur J Med Chem; 2019 May; 169():29-41. PubMed ID: 30852385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and biochemical characterization of a recombinant Anopheles gambiae tryptophan 2,3-dioxygenase expressed in Escherichia coli.
    Paglino A; Lombardo F; Arcà B; Rizzi M; Rossi F
    Insect Biochem Mol Biol; 2008 Sep; 38(9):871-6. PubMed ID: 18687401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.
    Seegers N; van Doornmalen AM; Uitdehaag JC; de Man J; Buijsman RC; Zaman GJ
    J Biomol Screen; 2014 Oct; 19(9):1266-74. PubMed ID: 24870017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
    Dolusić E; Larrieu P; Moineaux L; Stroobant V; Pilotte L; Colau D; Pochet L; Van den Eynde B; Masereel B; Wouters J; Frédérick R
    J Med Chem; 2011 Aug; 54(15):5320-34. PubMed ID: 21726069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of novel quinazoline-2,4-dione derivatives as chitin synthase inhibitors and antifungal agents.
    Ji Q; Yang D; Wang X; Chen C; Deng Q; Ge Z; Yuan L; Yang X; Liao F
    Bioorg Med Chem; 2014 Jul; 22(13):3405-13. PubMed ID: 24856180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological validation of TDO as a target for Parkinson's disease.
    Perez-Pardo P; Grobben Y; Willemsen-Seegers N; Hartog M; Tutone M; Muller M; Adolfs Y; Pasterkamp RJ; Vu-Pham D; van Doornmalen AM; van Cauter F; de Wit J; Gerard Sterrenburg J; Uitdehaag JCM; de Man J; Buijsman RC; Zaman GJR; Kraneveld AD
    FEBS J; 2021 Jul; 288(14):4311-4331. PubMed ID: 33471408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.